

Boehringer Ingelheim International GmbH · 55216 Ingelheim am Rhein

Product and Application Business Support European Medicines Agency Loading Dock Ontario Way London, E14 4HB UNITED KINGDOM

Boehringer Ingelheim International GmbH

10 June 2014

Reference: EMEA/H/C/003720/0000 Withdrawal of the Marketing Authorization Application for Faldaprevir Boehringer Ingelheim 120 mg soft capsules

Dear Sir or Madam,

The treatment environment for hepatitis C virus (HCV) infection has significantly and rapidly evolved since the submission of the marketing application for our investigational drug product "Faldaprevir Boehringer Ingelheim 120 mg soft capsules" (INN: faldaprevir) on 25 October 2013. There are now new treatment options available for patients, and additional all-oral interferon-free treatment options are expected to be available in the near future. Thus, there is no longer a significant unmet medical need for the faldaprevir interferon-based regimen that was the subject of our marketing authorization application. Boehringer Ingelheim (BI) has therefore taken a position globally that all marketing authorization applications currently under review for faldaprevir should be withdrawn.

Accordingly, on behalf of the applicant Boehringer Ingelheim International GmbH, we herein withdraw the marketing application for "Faldaprevir Boehringer Ingelheim 120 mg soft capsules".

BI wishes to extend our thanks to the Agency for many years of collegial and robust collaboration on the faldaprevir program.

Yours faithfully,

BOEHRINGER INGELHEIM INTERNATIONAL GMBH i.V. i.V.



Binger Strasse 173 55216 Ingelheim am Rhein Germany Phone +49 6132 77-0

+49 6132 72-0 www.boehringer-ingelheim.com

Board




Registered Office Ingelheim am Rhein Commercial Register Mainz HR B 21063

Deutsche Bank AG BIC: DEUTDE5MXXX IBAN: DE72 5507 0040 0012 2580 00



Copy to:



CHMP members & alternates